Company Profile
Rhythm Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- RYTM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
108.04 USD (+1.80%)
Close
Last updated: July 28, 2026
5.79B USD
Market cap
Why the stock is moving
As of Jul 28, 2026, RYTM closed up 1.80% at $108.04. No new same-company headline was identified in the current news window.
Company overview
Business overview
Rhythm Pharmaceuticals is an obesity and rare-disease company focused on melanocortin biology and severe genetic obesity disorders. Its lead franchise gives it a clear and focused therapeutic identity.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Rhythm sits in specialty biopharma.
Business Model Characteristics
The business combines commercial rare-disease execution with a pipeline aimed at additional obesity-related opportunities.
Position Within the Biotechnology Landscape
Rhythm is a focused metabolic and rare-disease name whose valuation is driven by commercial uptake and pipeline expansion.
Future catalysts
Rhythm Pharmaceuticals's catalysts are setmelanotide growth and any new melanocortin update that makes the rare-obesity franchise look more durable. The company’s story improves as the rare-disease base keeps expanding.
Recent news
- 01
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Source: Rhythm Pharmaceuticals
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Rhythm Pharmaceuticals (RYTM)?
Rhythm Pharmaceuticals (RYTM) most recently closed at 108.04 USD, a +1.80% move versus the previous session.
What is the market cap of Rhythm Pharmaceuticals (RYTM)?
Rhythm Pharmaceuticals currently has a market capitalization of 5.79B USD on BioPharmSignal.
What does Rhythm Pharmaceuticals do?
Rhythm Pharmaceuticals is an obesity and rare-disease company focused on melanocortin biology and severe genetic obesity disorders. Its lead franchise gives it a clear and focused therapeutic identity.
On which exchange is RYTM stock listed?
Rhythm Pharmaceuticals (RYTM) is associated with NASDAQ, United States, Biopharma.
What is Rhythm?
Rhythm Pharmaceuticals's catalysts are setmelanotide growth and any new melanocortin update that makes the rare-obesity franchise look more durable.
Which conditions is Rhythm Pharmaceuticals targeting with Rhythm?
Rhythm Pharmaceuticals is associated with obesity, genetic disease based on its company overview and current catalyst commentary.
How does Rhythm Pharmaceuticals describe recent progress with Rhythm?
Rhythm Pharmaceuticals's catalysts are setmelanotide growth and any new melanocortin update that makes the rare-obesity franchise look more durable.
What is Pharmaceuticals?
Rhythm Pharmaceuticals is an obesity and rare-disease company focused on melanocortin biology and severe genetic obesity disorders.